Searched for
NOVARTIS MALARIA MEDICINE
Anthropic appoints Indian-origin Novartis CEO Vas Narasimhan to its boardAnthropic’s Long-Term Benefit Trust is an independent governance body, designed to insulate key decisions as it scales its frontier AI syst...- The first drug to treat infants sick with malaria is approved by Swiss authoritySwissmedic has approved Coartem Baby, a malaria medicine specifically formulated for infants weighing 2 to 5 kilograms. This marks the firs...
- EU governments ban malaria drug for COVID-19, trial paused as safety fears growThe moves by France, Italy and Belgium followed a World Health Organization decision on Monday to pause a large trial of hydroxychloroquine...
- Novartis, Roche lift European shares as earnings jitters remainThe pan-European STOXX 600 index gained 0.2 per cent, after ending Friday with its biggest two-week percentage increase since 2015.
- Novartis, U.S. regulators agree to malaria drug hydroxychloroquine trial against COVID-19Novartis has reached an agreement with U.S. regulators to hold a randomized trial of generic malaria drug hydroxychloroquine against COVID-...
- Novartis scraps sale of assets including COVID-19 hopeful to India's AurobindoNovartis AG on Thursday scrapped the $1 billion sale of U.S. generic pill and skin drug assets to India's Aurobindo Pharma Ltd as regulator...
- Malaria medicine 'Hydroxychloroquine' being administered to 1,100 COVID19 patients in New York: US President Donald TrumpAn inexpensive drug widely used since 1955 to treat malaria, Hydroxychloroquine is considered to have relatively harmless side effects. It ...
- Novartis CEO says Malaria drug is biggest hope against coronavirus - SonntagsZeitungOther companies including Bayer and Teva have also agreed to donate hydroxychloroquine or similar drugs, while Gilead Sciences is testing i...
- There’s an explosion of data & digital opportunities in Indian healthcare: Vasant Narasimhan, CEO, NovartisOur chief focus for future investments will be: One on increasing our R&D footprint here over time. Second is data and digital.
- US watch list may hit affordable drug businessIndia remains on Priority Watch List, and continues to be singled out for what the USTR considers to be inadequate protection of intellectu...
- Cipla asks government to revoke five patents held by NovartisCipla, India’s fifthlargest drugmaker by revenue, has asked the government to revoke five patents that Novartis holds on respiratory drug O...
- Fake & sub-standard drugs: India, China may be worst offendersDespite efforts globally, sales of fake medicines are rising rapidly, and the menace could be worse than the health threat posed by Big Tob...
- MNC, domestic pharma cos lock horns over patents in IndiaMNC durgmakers on Wednesday hit back at their domestic counterparts over frivolous patent issue and said even the local firms are engaged i...
- 'Corporations need to work with govt'PepsiCo's Indra Nooyi and Novartis' Daniel Vasella discuss challenges before post-crisis 21st century corporations.
- NPPA revision of 174 drug prices may lead to costlier medicinesInsulin brands, steroids and painkillers may become more expensive once NPPA revises prices of more than 170 medicines, in some cases by as...
- Rural India writes pharma fortunesAccording to a research, the Indian pharma market in rural areas has witnessed a 39% growth.
Load More
